In agreement with our previous work on melanoma and breast cancer cells, RCC cells that express mGluR1 also release excess glutamate into extracellular environment and are sensitive to riluzole treatment supporting the notion that sustained mGluR1 signaling is required for tumor progression [145]. This evidence concerns the gene GRM1 and breast cancer.